The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Mechanisms of Disease
PreviousPrevious
Volume 350:1535-1548 April 8, 2004 Number 15
NextNext

Acute Lymphoblastic Leukemia
Ching-Hon Pui, M.D., Mary V. Relling, Pharm.D., and James R. Downing, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
The rate of success in the treatment of acute lymphoblastic leukemia (ALL) has increased steadily since the 1960s. The five-year event-free survival rate is nearly 80 percent for children with ALL and approximately 40 percent for adults (Table 1).1,2,3,4,5,6,7,8,9 If we include cases of relapsed ALL that respond well to so-called remission retrieval therapy, the rates of cure (defined by the absence of evidence of disease for at least 10 years) with the use of modern treatments are about 80 percent for children and 40 percent for adults.10,11 Attempts to boost cure rates further with the use of . . . [Full Text of this Article]

Molecular Genetic Alterations

Primary Abnormalities

Chimeric Transcription Factors

            The TEL-AML1 Fusion Gene

            Translocations Involving the MLL Gene

            Other HOX Genes and HOX Cofactors

Cooperative Mutations

            The FLT-3 Receptor

            The Retinoblastoma Pathways

            TP53

Prognostic Factors

Sensitivity to Chemotherapy

Influence of Age

Gene-Expression Profiling

Molecular Epidemiology

In Utero Development of All

Age at Presentation

Genetic Polymorphisms

            Detoxifying Enzymes

            Folate-Metabolizing Enzymes

Pharmacogenetics

Future Directions


Source Information

From the Departments of Hematology/Oncology (C.-H.P.), Pharmaceutical Sciences (M.V.R.), and Pathology (C.-H.P., J.R.D.), St. Jude Children's Research Hospital; and the Colleges of Medicine (C.-H.P., M.V.R., J.R.D.) and Pharmacy (M.V.R.), University of Tennessee Health Science Center — both in Memphis.

Address reprint requests to Dr. Pui at St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105, or at ching-hon.pui@stjude.org.


Related Letters:

Magnetic Fields and Leukemia
Hocking B., Pui C.-H., Relling M. V., Downing J. R.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:102, Jul 1, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.